Clinical application and limitations of interferon-γ release assays for the diagnosis of latent tuberculosis infection

Clinical Infectious Diseases

Volumn 52, Issue 8, 2011, Pages 1031-1037

  Herrera, Victor ^a   Perry, Sharon ^a   Parsonnet, Julie ^a   Banaei, Niaz ^a,b,c,d  

^a Division of Geographic Medicine and Infectious Diseases   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GAMMA INTERFERON;

ARTICLE; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CYTOKINE RELEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; PRIORITY JOURNAL; REPRODUCIBILITY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; TUBERCULIN TEST; TUBERCULOSIS;

BACTERIOLOGICAL TECHNIQUES; HUMANS; IMMUNOASSAY; INTERFERON-GAMMA; LATENT TUBERCULOSIS;

EID: 79953875948     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir068     Document Type: Article

References (54)

1. Organization WH. Global tuberculosis control: surveillance, planning, financing. Geneva, Switzerland: World Health Organization, 2009.
2. Grzybowski S, Barnett GD, Styblo K. Contacts of cases of active pulmonary tuberculosis. Bull Int Union Tuberc 1975; 50:90-106.
3. Comstock GW, Cauthen GM. Epidemiology of tuberculosis. In: Reichman L, Herschfield E, eds. Tuberculosis: a comprehensive approach. New York, New York: Marcel Decker, Inc, 1993: 23-48.
4. Shaw JB, Wynn-Williams N. Infectivity of pulmonary tuberculosis in relation to sputum status. Am Rev Tuberc 1954; 69:724-32.
5. Bennett DE, Courval JM, Onarato I, et al. Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999-2000. Am J Respir Crit Care Med 2008; 177:348-55. (Pubitemid 351198380)
6. Li J, Munsiff SS, Agerton TB. Prevalence of tuberculin skin test Posi-tivity in clinical population in New York City. J Immigr Minor Health 2010; 12(6);816-22.
7. Varkey P, Jerath AU, Bagniewski SM, Lesnick TG. The epidemiology of tuberculosis among primary refugee arrivals in Minnesota between 1997 and 2001. Travel Med 2007; 14:1-8.
8. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 2000; 49:1-51.
9. Kaufmann SH. Protection against tuberculosis: cytokines, T cells, and macrophages. Ann Rheum Dis 2002; 61(suppl. 2):ii54-8. (Pubitemid 35221715)
10. Mazurek M, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection-United States, 2010. MMWR Recomm Rep 2010; 59:1-25.
11. Cellestis L. QuantiFERON-TB GOLD [Package insert]. Available at: http://www.cellestis.com. Accessed 4 October 2010.
12. Oxford Immunotec L. T-Spot TB [US package insert]. Available at: http://www.oxfordimmunotec.com. Accessed 4 October 2010.
13. Andersen P, Munk ME, Pollock JM, Doherty TM. Specific immune-based diagnosis of tuberculosis. Lancet 2000; 356:1099-104.
14. Menzies R, Vissandjee B, Rocher I, St. Germain Y. The booster effect in two-step tuberculin testing among young adults in montreal. Ann Intern Med 1994; 120:190-8.
15. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161:S221-47.
16. Jekel JF, Greenberg RA, Drake BM. Influence of the prevalence of infection on tuberculin skin testing programs. Public Health Rep 1969; 84:883-6.
17. Lee SW, Oh DK, Lee SH, Kang HY, Lee CT, Yim JJ. Time interval to conversion of interferon-c release assay after exposure to tuberculosis. Eur Respir J 2010. Epub 2010 Dec 9.
18. Jensen PA, Lambert LA, Iademarco MF, Ridzon R. Guidelines for preventing the transmission of Mycobacterium tuberculosis in healthcare settings, 2005. MMWR Recomm Rep 2005; 54:1-141.
19. Ferrara G, Losi M, D'Amico R, et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobac-terium tuberculosis: a prospective study. Lancet 2006; 367:1328-34.
20. Kik SV, Franken WP, Mensen M, et al. Predictive value for progression to tuberculosis by IGRA and TST in immigrant contacts. Eur Respir J 2010; 35:1346-53.
21. Diel R, Loddenkemper R, Niemann S, Meywald-Walter K, Nienhaus A. Negative and positive predictive value of a whole-blood IGRA for developing active TB-An update. Am J Respir Crit Care Med 2011; 183(1);88-95.
22. Diel R, Loddenkemper R, Meywald-Walter K, Gottschalk R, Nienhaus A. Comparative performance of tuberculin skin test, Quanti FERON-TB-Gold in tube assay, and T-SpotTB test in contact investigations for tuberculosis. Chest 2009; 135:1010-8.
23. Soysal A, Torun T, Efe S, Gencer H, Tahaoglu K, Bakir M. Evaluation of cut-off values of interferon-gamma-based assays in the diagnosis of M. tuberculosis infection. Int J Tuberc Lung Dis 2008; 12:50-6.
24. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008; 149:177-84.
25. Brock I, Weldingh K, Lillebaek T, Follmann F, Andersen P. Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts. Am J Respir Crit Care Med 2004; 170:65-9. (Pubitemid 38997753)
26. Yoshiyama T, Harada N, Higuchi K, Sekiya Y, Uchimura K. Use of the QuantiFERON (R)-TB Gold test for screening tuberculosis contacts and predicting active disease. Int J Tuberc Lung Dis 2010; 14:819-27.
27. del Corral H, Paris SC, Marin ND, et al. IFNgamma response to My-cobacterium tuberculosis, risk of infection and disease in household contacts of tuberculosis patients in Colombia. PLoS One 2009; 4:e8257.
28. Hill PC, Jackson-Sillah DJ, Fox A, et al. Incidence of tuberculosis and the predictive value of ELISPOT and Mantoux tests in Gambian case contacts. PLoS One 2008; 3:e1379.
29. Horsburgh CR Jr. Priorities for the treatment of latent tuberculosis infection in the United states. N Engl J Med 2004; 350:2060-71115.
30. Andersen P, Doherty TM, Pai M, Weldingh K. The prognosis of latent tuberculosis: can disease be predicted? Trends Mol Med 2007; 13:175-82. (Pubitemid 46687128)
31. Pai M. Spectrum of latent tuberculosis - existing tests cannot resolve the underlying phenotypes. Nat Rev Microbiol 2010; 8:242
32. Menzies D, Joshi R, Pai M. Risk of tuberculosis infection and disease associated with work in health care settings. Int J Tuberc Lung Dis 2007; 11:593-605. (Pubitemid 46868618)
33. Detjen AK, Loebenberg L, Grewal HM, et al. Short-term re-producibility of a commercial interferon gamma release assay. Clin Vaccine Immunol 2009; 16:1170-5.
34. Pai M, Joshi R, Dogra S, et al. T-cell assay conversions and reversions among household contacts of tuberculosis patients in rural India. Int J Tuberc Lung Dis 2009; 13:84-92.
35. Ewer K, Millington KA, Deeks JJ, Alvarez L, Bryant G, Lalvani A. Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. Am J Respir Crit Care Med 2006; 174:831-9. (Pubitemid 44511666)
36. Veerapathran A, Joshi R, Goswami K, et al. T-cell assays for tuberculosis infection: deriving cut-offs for conversions using reproducibility data. PLoS One 2008; 3:e1850.
37. Herrera V, Yeh E, Murphy K, Parsonnet J, Banaei N. Immediate incubation reduces indeterminate results for QuantiFERON-TB Gold in-tube assay. J Clin Microbiol 2010; 48:2672-6.
38. Pai M, Joshi R, Dogra S, et al. Serial testing of health care workers for tuberculosis using interferon-c assay. Am J Respir Crit Care Med 2006; 174:349-55. (Pubitemid 44156616)
39. Lighter J, Rigaud M, Eduardo R, Peng CH, Pollack H. Latent tuberculosis diagnosis in children by using the QuantiFERON-TB Gold In-Tube test. Pediatrics 2009; 123:30-7.
40. Connell TG, Ritz N, Paxton GA, Buttery JP, Curtis N, Ranganathan SC. A three-way comparison of tuberculin skin testing, QuantiFERON-TB gold and T-SPOT.TB in children. PloS one 2008; 3:e2624.
41. Bamford AR, Crook AM, Clark JE, et al. Comparison of interferon-c release assays and tuberculin skin test in predicting active tuberculosis (TB) in children in the UK: a paediatric TB network study. Arch Dis Child 2010; 95:180-6.
42. Adetifa IM, Ota MO, Jeffries DJ, et al. Commercial interferon gamma release assays compared to the tuberculin skin test for diagnosis of latent Mycobacterium tuberculosis infection in childhood contacts in the Gambia. Pediatr Infect Dis JPediatr 2010; 29:439-43.
43. Kampmann B, Whittaker E, Williams A, et al. Interferon-gamma release assays do not identify more children with active tuberculosis than the tuberculin skin test. Eur Respir J 2009; 33:1374-82.
44. Lewinsohn DA, Lobato MN, Jereb JA. Interferon-gamma release assays: new diagnostic tests for Mycobacterium tuberculosis infection, and their use in children. Curr Opin Pediatr 2010; 22:71-6.
45. Newton SM, Brent AJ, Anderson S, Whittaker E, Kampmann B. Pae-diatric tuberculosis. Lancet Infect Dis 2008; 8:498-510.
46. Perry S, Sanchez L, Yang S, Agarwal Z, Hurst P, Parsonnet J. Re-producibility of QuantiFERON-TB gold in-tube assay. lin Vaccine Immunol 2008; 15:425-32. (Pubitemid 351967072)
47. van Zyl-Smit RN, Pai M, Peprah K, et al. Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing. Am J Respir Crit Care Med 2009; 180:49-58.
48. Lee SH, Lew WJ, Kim HJ, et al. Serial interferon-gamma release assays after rifampicin prophylaxis in a tuberculosis outbreak. Respir Med 2010; 104:448-53.
49. Bosshard V, Roux-Lombard P, Perneger T, et al. Do results of the T-SPOT.TB interferon-c release assay change after treatment of tuberculosis? Respir Med 2009; 103:30-4.
50. Dheda K, van Zyl Smit R, Badri M, Pai M. T-cell interferon-gamma release assays for the rapid immunodiagnosis of tuberculosis: clinical utility in high-burden vs. low-burden settings. Curr Opin Pulm Med 2009; 15:188-200.
51. Arend SM, Thijsen SFT, Leyten EMS, et al. Comparison of two in-terferon-c assays and tuberculin skin test for tracing tuberculosis contacts. Am J Respir Crit Care Med 2007; 175:618-27. (Pubitemid 46438947)
52. van Zyl-Smit RN, Zwerling A, Dheda K, Pai M. Within-subject variability of interferon-g assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review. PLoS One 2009; 4:e8517.
53. Smith SG, Joosten SA, Verscheure V, et al. Identification of major factors influencing ELISpot-based monitoring of cellular responses to antigens from Mycobacterium tuberculosis. PLoS One 2009; 4:e7972.
54. Lienhardt C, Fielding K, Hane AA, et al. Evaluation of the prognostic value of IFN-gamma release assay and tuberculin skin test in household contacts of infectious tuberculosis cases in Senegal. PLoS One 2010; 5:e10508.